Again, the source is Business Week -- but interesting, nonetheless, given the burgeoning litigation profile of the hormone-driven (birth-control) portions of the businessses:
. . . .Teva Pharmaceutical Industries, the Israeli generic drugmaker known for its Pac-Man-like acquisitions of smaller competitors, aims to triple its annual sales in the category of women's health to $1 billion as early as 2012. A large portion of the $650 million Teva needs to reach that goal is likely to come from birth-control products the company acquires in future deals.
CEO Shlomo Yanai told analysts earlier this month that Teva has its eye on several targets, though he didn't name names. Frances Cloud, an independent London-based analyst who has covered the drug industry for 23 years, says Teva could be looking at the women's health divisions of U.S.-based Merck or Abbott Laboratories. "We wouldn't rule anything out," says Bill Marth, chief executive of Teva's North American operations. . . .
Personally, I rather doubt it. New Merck seems to enjoy running litigation-magnet business lines.
No comments:
Post a Comment